- Home
- VMEO vs REPL Comparison
VMEO vs REPL Comparison
Compare VMEO & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VMEO
- REPL
- Stock Information
- Founded
- VMEO 2004
- REPL 2015
- Country
- VMEO United States
- REPL United States
- Employees
- VMEO N/A
- REPL N/A
- Industry
- VMEO Computer Software: Prepackaged Software
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- VMEO Technology
- REPL Health Care
- Exchange
- VMEO Nasdaq
- REPL Nasdaq
- Market Cap
- VMEO 668.9M
- REPL 757.8M
- IPO Year
- VMEO N/A
- REPL 2018
- Fundamental
- Price
- VMEO $4.00
- REPL $11.09
- Analyst Decision
- VMEO Buy
- REPL Strong Buy
- Analyst Count
- VMEO 4
- REPL 7
- Target Price
- VMEO $7.35
- REPL $20.83
- AVG Volume (30 Days)
- VMEO 2.1M
- REPL 1.3M
- Earning Date
- VMEO 08-04-2025
- REPL 08-07-2025
- Dividend Yield
- VMEO N/A
- REPL N/A
- EPS Growth
- VMEO N/A
- REPL N/A
- EPS
- VMEO 0.10
- REPL N/A
- Revenue
- VMEO $415,130,000.00
- REPL N/A
- Revenue This Year
- VMEO $3.90
- REPL N/A
- Revenue Next Year
- VMEO $6.17
- REPL N/A
- P/E Ratio
- VMEO $38.95
- REPL N/A
- Revenue Growth
- VMEO N/A
- REPL N/A
- 52 Week Low
- VMEO $3.45
- REPL $6.44
- 52 Week High
- VMEO $7.90
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- VMEO 42.02
- REPL 68.18
- Support Level
- VMEO $3.90
- REPL $9.26
- Resistance Level
- VMEO $4.08
- REPL $9.90
- Average True Range (ATR)
- VMEO 0.12
- REPL 0.59
- MACD
- VMEO 0.03
- REPL 0.14
- Stochastic Oscillator
- VMEO 68.52
- REPL 91.56
About VMEO Vimeo Inc.
Vimeo Inc is the all-in-one video software solution, providing the full breadth of video tools through a software-as-a-service model. The comprehensive and cloud-based tools of the company empower its users to create, share, collaborate and communicate with video on a single, turnkey platform. The company derives its revenue from SaaS subscription fees paid by customers for subscription plans.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.